ESC 365 - Advanced echocardiographic features, three-dimensional Left Ventricular-Arterial Coupling and vascular function in childhood cancer survivors exposed to anthracycline chemotherapy

Open Access

Advanced echocardiographic features, three-dimensional Left Ventricular-Arterial Coupling and vascular function in childhood cancer survivors exposed to anthracycline chemotherapy

Session: Heart Failure ePosters - focus on Comorbidities and special population

Topic: Cardio-Oncology

Speaker: Doctor M. Camilli (Rome, IT)

Event: Heart Failure 2022

Congress Session

About the speaker

Doctor Massimiliano Camilli

Catholic University of the Sacred Heart, Rome (Italy)

0 follower

35 more presentations in this session

A brazilian perspective about the impact of covid 19 on hospitalizations for venous tromboembolism and pulmonary embolism

Speaker: Mr E. Biscarde (BR)

Diastolic disfunction in precapillary pulmonary hypertension - looking left to see right

Speaker: Doctor P. Alves da Silva (Lisbon, PT)

Pulmonary hypertension in connective tissue diseases with overt of features of venous/capillaries involvement: clinical implications and prognostic impact of this phenotype.

Speaker: Doctor J. Grade Santos (Almada, PT)

Risk stratification in pulmonary arterial hypertension: do our patients benefit from a 4-strata model?

Speaker: Doctor J. Grade Santos (Almada, PT)

Comparison of risk scores calculators in patients newly diagnosed with pulmonary arterial hypertension.

Speaker: Doctor J. Grade Santos (Almada, PT)

Access the full session

Heart Failure ePosters - focus on Comorbidities and special population

Speakers: Doctor M. Camilli, Mr E. Biscarde, Doctor P. Alves da Silva, Doctor J. Grade Santos, Doctor J. Grade Santos...

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

Related content

Open Access

Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved

21 May 2022

Open Access

Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial

21 May 2022

This platform is supported by